首页> 美国卫生研究院文献>Frontiers in Oncology >Clinical Efficacy of CyberKnife Radiosurgery for Adult Brainstem Glioma: 10 Years Experience at Tianjin CyberKnife Center and Review of the Literature
【2h】

Clinical Efficacy of CyberKnife Radiosurgery for Adult Brainstem Glioma: 10 Years Experience at Tianjin CyberKnife Center and Review of the Literature

机译:射波刀治疗成人脑干神经胶质瘤的临床疗效:天津射波刀中心十年经验及文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Brainstem glioma is a rare brain tumor with poor prognosis and difficulty for surgical resection. We sought to retrospectively analyze and evaluate the clinical efficacy of CyberKnife for brainstem gliomas.Methods: From 2006 to 2015, a total of 21 brainstem gliomas patients who received CyberKnife radiosurgery treatment enrolled in this study and 18 patients with follow up. CyberKnife image-guided radiosurgical system were applied consecutively with the median prescribed total dose of 26 Gy (14–33 Gy) at two to six fractions on days utilizing CyberKnife system, and the median biological equivalent doses of 59.8 Gy (33.6–76.56 Gy). The clinic pathlogical features, survival were analyzed to explore the efficacy of CyberKnife radiosurgery in treatment of brainstem glioma.Results: With median follow-up of 54.5 months, patients with brainstem gliomas had median overall survival of 19 months, five patients still alive. The primary endpoints of the 1- and 2-year overall survival rates were 87.5 and 52.4%, respectively. During the treatment course, six patients were observed to have pseudoprogression with mass effect on MRI. Four patients developed radiation complications. Grade 2 radiation-related toxicity were observed in three patients and one patient with grade 3.Conclusion: The efficacy of brainstem gliomas—treated with CyberKnife is efficacious with mild toxicity.
机译:背景:脑干神经胶质瘤是一种罕见的脑肿瘤,预后差,难以手术切除。我们试图回顾性分析和评估射波刀治疗脑干神经胶质瘤的临床疗效。方法:从2006年至2015年,该研究共纳入21例接受射波刀放射外科治疗的脑干神经胶质瘤患者,其中18例跟进。连续使用射波刀影像引导的放射外科手术系统,使用射波刀系统,按规定的中位数规定总剂量中位数为26 Gy(14–33 Gy),分两至六天使用,而中位生物等效剂量为59.8 Gy(33.6–76.56 Gy) 。分析临床病理特点,生存率,以探讨射波刀放射治疗脑干神经胶质瘤的疗效。结果:中位随访54.5个月,脑干神经胶质瘤患者中位总体生存期为19个月,五名患者还活着。 1年和2年总生存率的主要终点分别为87.5%和52.4%。在治疗过程中,观察到6例患者的假进展对MRI有质量影响。四名患者出现了放射并发症。在3例患者和1例3级患者中观察到2级辐射相关毒性。结论:用射波刀治疗脑干神经胶质瘤疗效确切,毒性轻。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号